Developing vaccines for an aging population

Science Translational Medicine

Volumn 7, Issue 281, 2015, Pages

  Black, Steven ^a   De Gregorio, Ennio ^b   Rappuoli, Rino ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MALARIA VACCINE; VACCINE;

ADAPTIVE IMMUNITY; AGING; CLINICAL EFFECTIVENESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INNATE IMMUNITY; MALARIA; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VACCINATION; VACCINE PRODUCTION; DRUG DEVELOPMENT; ECONOMICS; HEALTH CARE COST; IMMUNOLOGY; PROCEDURES; PUBLIC HEALTH;

AGING; DRUG DISCOVERY; HEALTH CARE COSTS; HUMANS; PUBLIC HEALTH; VACCINES;

EID: 84926470559     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa0722     Document Type: Review

References (38)

1. www.who.int/immunization/global-vaccine-action-plan/GVAP-doc-2011-2020/en/index.html; accessed 7 August 2014, page 12.
2. www.cdc.gov/nchs/fastats/life-expectancy.html.
3. demog.berkeley.edu/~andrew/1918/figure2.html.
4. www.un.org/esa/population/publications/worldageing19502050/pdf/80chapterii.pdf; accessed 8 August 2014.
5. D. S. Jones, S. H. Podolsky, J. A. Greene, The burden of disease and the changing task of medicine. N. Engl. J. Med. 366, 2333-2338 (2012).
6. B. Weinberger, D. Herndler-Brandstetter, A. Schwanninger, D. Weiskopf, B. Grubeck-Loebenstein, Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46, 1078-1084 (2008).
7. B. Kwak, F. Mulhaupt, S. Myit, F. Mach, Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402 (2000).
8. T. Querec, S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, B. Pulendran, Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006).
9. T. Vesikari, M. Knuf, P. Wutzler, A. Karvonen, D. Kieninger-Baum, H. J. Schmitt, F. Baehner, A. Borkowski, T. F. Tsai, R. Clemens, Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406-1416 (2011).
10. S. Mannino, M. Villa, G. Apolone, N. S. Weiss, N. Groth, I. Aquino, L. Boldori, F. Caramaschi, A. Gattinoni, G. Malchiodi, K. J. Rothman, Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am. J. Epidemiol. 176, 527-533 (2012).
11. T. F. Schwarz, M. Spaczynski, A. Schneider, J. Wysocki, A. Galaj, P. Perona, S. Poncelet, T. Zahaf, K. Hardt, D. Descamps, G. Dubin, HPV Study Group for Adult Women, Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27, 581-587 (2009).
12. G. Boland, J. Beran, M. Lievens, J. Sasadeusz, P. Dentico, H. Nothdurft, J. N. Zuckerman, B. Genton, R. Steffen, L. Loutan, J. Van Hattum, M. Stoffel, Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23, 316-320 (2004).
13. K. A. Bojang, P. J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, K. E. Kester, W. R. Ballou, D. J. Conway, W. H. Reece, P. Gothard, L. Yamuah, M. Delchambre, G. Voss, B. M. Greenwood, A. Hill, K. P. McAdam, N. Tornieporth, J. D. Cohen, T. Doherty, RTS, S Malaria Vaccine Trial Team, Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 358, 1927-1934 (2001).
14. S. A. Halperin, B. J. Ward, M. Dionne, J. M. Langley, S. A. McNeil, B. Smith, D. Mackinnon-Cameron, W. L. Heyward, J. T. Martin, Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum. Vaccin. Immunother. 9, 1438-1444 (2013).
15. A. T. Glenny, M. Barr, The precipitation of diphtheria toxoid by potash alum. J. Pathol. Bacteriol. 34, 131-138 (1931).
16. P. Marrack, A. S. McKee, M. W. Munks, Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293 (2009).
17. S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, A. Podda, Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17, 3094-3101 (1999).
18. V. Schultze, V. D'Agosto, A. Wack, D. Novicki, J. Zorn, R. Hennig, Safety of MF59 adjuvant. Vaccine 26, 3209-3222 (2008).
19. M. Villa, S. Black, N. Groth, K. J. Rothman, G. Apolone, N. S. Weiss, I. Aquino, L. Boldori, F. Caramaschi, A. Gattinoni, G. Malchiodi, A. Crucitti, G. Della Cioppa, E. Scarpini, D. Mavilio, S. Mannino, Safety of MF59-adjuvanted influenza vaccination in the elderly: Results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am. J. Epidemiol. 178, 1139-1145 (2013).
20. T. Heikkinen, J. Young, E. van Beek, H. Franke, T. Verstraeten, J. G. Weil, G. Della Cioppa, Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: A comparative cohort study. Am. J. Obstet. Gynecol. 207, 177.e1-177.e8 (2012).
21. H. C. Nauts, W. E. Swift, B. L. Coley, The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 6, 205-216 (1946).
22. A. M. Didierlaurent, S. Morel, L. Lockman, S. L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti, D. Larocque, M. Van Mechelen, N. Garçon, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197 (2009).
23. M. L. Mbow, E. De Gregorio, N. M. Valiante, R. Rappuoli, New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411-416 (2010).
24. M. Barry, C. Cooper, Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther. 7, 1731-1737 (2007).
25. R. N. Coler, S. Bertholet, M. Moutaftsi, J. A. Guderian, H. P. Windish, S. L. Baldwin, E. M. Laughlin, M. S. Duthie, C. B. Fox, D. Carter, M. Friede, T. S. Vedvick, S. G. Reed, Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLOS ONE 6, e16333 (2011).
26. Q. Zhu, C. Egelston, A. Vivekanandhan, S. Uematsu, S. Akira, D. M. Klinman, I. M. Belyakov, J. A. Berzofsky, Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. Proc. Natl. Acad. Sci. U.S.A. 105, 16260-16265 (2008).
27. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
28. E. Muyanja, A. Ssemaganda, P. Ngauv, R. Cubas, H. Perrin, D. Srinivasan, G. Canderan, B. Lawson, J. Kopycinski, A. S. Graham, D. K. Rowe, M. J. Smith, S. Isern, S. Michael, G. Silvestri, T. H. Vanderford, E. Castro, G. Pantaleo, J. Singer, J. Gillmour, N. Kiwanuka, A. Nanvubya, C. Schmidt, J. Birungi, J. Cox, E. K. Haddad, P. Kaleebu, P. Fast, R. P. Sekaly, L. Trautmann, D. Gaucher, Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124, 3147-3158 (2014).
29. K. Araki, A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, R. Ahmed, mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 (2009).
30. J. B. Mannick, G. Del Giudice, M. Lattanzi, N. M. Valiante, J. Praestgaard, B. Huang, M. A. Lonetto, H. T. Maecker, J. Kovarik, S. Carson, D. J. Glass, L. B. Klickstein, mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).
31. S. Black, The role of health economic analyses in vaccine decision making. Vaccine 31, 6046-6049 (2013).
32. E. Rosenthal, "Why vaccines are sometime unavailable," New York Times, 31 July 2014.
33. www.cdc.gov/meningococcal/outbreaks/princeton.html.
34. C. Phelps, G. Madhavan, K. Sangha, R. Rappuoli, R. R. Colwell, R. M. Martinez, P. Kelley, L. King, A priority-setting aid for new vaccine candidates. Proc. Natl. Acad. Sci. U.S.A. 111, 3199-3200 (2014).
35. D. E. Bloom, D. Canning, M. Weston, The value of vaccination. World Economics - Henley on Thames 6, 15 (2005).
36. T. Bärnighausen, D. Bloom, E. T. Cafiero-Fonseca, J. C. O'Brien, Valuing vaccines. Proc. Natl. Acad. Sci. U.S.A. 111, 12313-12319 (2014).
37. C. G. Whitney, F. Zhou, J. Singleton, A. Schuchat, Centers for Disease Control and Prevention (CDC), Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR 63, 352-355 (2014).
38. P. J. Neumann, J. T. Cohen, M. C. Weinstein, Updating cost-effectiveness - The curious resilience of the $50,000-per-QALY threshold. N. Engl. J. Med. 371, 796-797 (2014).